Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.
PER Pulse™ Recap
for Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference® focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of expert perspectives on case management decisions is provided in these summaries.
This activity is supported by educational grants from AbbVie, Acelity, Astellas, AstraZeneca, Celgene, Eisai Inc., Genentech, Inc., Genomic Health, Inc., Lilly, Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, Puma Biotechnology, Inc, and TESARO, Inc.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
In this episode of Clinical Case Vignette Series™: 33rd Annual Miami Breast Cancer Conference®, content from this year's conference held on March 11-13, 2016, will be covered. This activity consists of a series of interviews with renowned experts Elizabeth Mittendorf, MD, PhD, and Andrew D. Seidman, MD, which explore topics that are clinically relevant to the practicing community clinician. Important topics that are key to evolving treatment paradigms for patients with breast cancer are reviewed, such as the management of HR+/HER2+ locally invasive disease and axilla in early-stage clinically node-negative disease. A look at some of the more exciting emerging strategies in the field are also reviewed, including an update on vaccine development for HER2+ disease and immune checkpoint blockade in the setting of triple-negative breast cancer.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.
Elizabeth Mittendorf, MD, PhD
Associate Professor and Deputy Chair for Research
Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Andrew D. Seidman, MD
Attending Physician, Breast Cancer Medicine Service
Memorial Sloan Kettering Cancer Center
New York, NY
The staff of Physicians' Education Resource®, LLC
The following individuals have relevant financial relationships with commercial interests to disclose:
Elizabeth Mittendorf, MD, PhD - Institution Funding: Galena Biopharma, Antigen Express; Andrew D. Seidman, MD - Grant/Research Support: Novartis, Bayer; Consultant: Novartis, Genentech, Merrimack, Kadmon, Pfizer; Speakers Bureau: Celgene, Genomic Health, Novartis,Genentech, Eisai
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018